Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Dexamethasone Phosphate Ophthalmic Solution
EGP-437 1.6 mA-min at 0.4 with EyeGate II System · 1 trial · 1 indication
Proportion of subjects with an anterior chamber cell (ACC) score of zero at Days 14 and 28
| Arm | Type | Description |
|---|---|---|
| EGP-437 1.6 mA-min at 0.4 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP 437 1.6 mA-min at 0.4 mA |
| EGP-437 4.8 mA-min at 1.2 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 4.8 mA-min at 1.2 mA |
| EGP-437 10.0 mA-min at 2.5 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 10.0 mA-min at 2.5 mA |
| EGP-437 14.0 mA-min at 3.5 mA | ACTIVE_COMPARATOR | Ocular iontophoresis with EGP-437 14.0 mA-min at 3.5 mA |
| Name | Type | Description |
|---|---|---|
| EGP-437 1.6 mA-min at 0.4 with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System |
| EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System | DRUG | Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System |
Inclusion Criteria: • Non-infectious anterior uveitis Exclusion Criteria: * Uveitis of infectious etiology * Previous anterior uveitis episode ≤ 4 weeks prior to baseline * Intraocular pressure (IOP) ≥ 25 mmHg at baseline, a history of glaucoma, and/or patients who require ocular anti-hypertensiv...
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is an investigational small molecule therapy delivered using the EyeGate II iontophoresis system. It is being developed by Kiora Pharmaceuticals, Inc. for the treatment of anterior uveitis, an inflammatory condition of the front part of the eye.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is being studied for the treatment of anterior uveitis. Anterior uveitis is an inflammatory condition affecting the front portion of the eye. The drug is delivered via the EyeGate II System, which uses iontophoresis to move the therapy into ocular tissue.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is developed by Kiora Pharmaceuticals, Inc., which trades under the ticker KPRX. Kiora is a clinical-stage biopharmaceutical company focused on ophthalmology. The EyeGate II System is the delivery platform paired with the drug in this program.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System is in Phase 2 development. It is an investigational therapy and has not been approved by the FDA. The program has completed one Phase 2 clinical trial evaluating the combination of iontophoresis and dexamethasone phosphate for anterior uveitis.
EGP-437 1.6 mA-min at 0.4 with EyeGate II System has been evaluated in one completed Phase 2 trial, NCT00694135, titled Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis. The trial enrolled 40 participants across the United States and India and was randomized, double-blind, and active-controlled.